CD86

Across TCGA pan-cancer cohorts, CD86 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of CD86’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CD86 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CD86 is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

KIRC, HNSC, and KIRP are the cancer types where CD86 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD86 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+2.409	<.001	12	view →
HNSC	Female	III,IV	+1.472	<.001	11	view →
KIRP	Male	All	+1.556	<.001	9	view →
LUSC	Male	II,III,IV	−1.381	<.001	8	view →
LUAD	All	II,III,IV	−0.732	<.001	8	view →
STAD	Female	All	+1.828	<.001	7	view →
THCA	All	III,IV	+1.000	.003	7	view →
BRCA	Female	All	+0.749	<.001	6	view →
PAAD	All	All	−1.567	.023	2	view →
ESCA	All	All	+1.666	.007	1	view →
BLCA	All	IV	+1.037	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

CD86–KIRC

Open the KIRC breakdown →